在体外,Galega officinalis 提取物具有抗糖尿病和抗氧化作用
Shokoofeh Sukhtezari1, Mohammad Ali Sahari1, Mohsen Barzegar1
1Department of Food Science and Technology, Faculty of Agriculture Tarbiat Modares University Tehran Iran.
Food science & nutrition
|October 31, 2024
概括
该研究发现,一种酸盐-水 (90:10) 溶剂有效地从Galega officinalis中提取化合物,产生强大的抗氧化和抗糖尿病特性. 这种提取物显示出管理血糖水平和打击氧化应激的巨大潜力.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 树 (Galega officinalis,简称GO) 是一种具有传统医药用途的植物.
- 了解其植物化学成分和生物活性对于治疗应用至关重要.
- 溶剂提取是从药用植物中分离生物活性化合物的关键方法.
研究的目的:
- 为了确定Galega officinalis提取物中,黄和蛋白的总含量.
- 评估不同GO提取物的抗氧化活性和体外抗糖尿病潜力.
- 确定从Galega officinalis提取生物活性化合物的最佳溶剂.
主要方法:
- 使用各种溶剂系统 (水,A90,A70,E20) 进行了溶剂提取.
- 总含量 (TPC),总黄含量 (TFC) 和素的量化.
- 对抗氧化活性 (ABTS,基,DPPH,FRAP,金属化) 和抗糖尿病潜力 (抑制糖酶,α-氨酶,α-葡萄糖酶,马尔塔酶) 的测定.
主要成果:
- 水溶剂产生了最高的提取产量和素含量.
- A90 (乙-水,90:10) 溶剂产生了最高的TPC和TFC.
- A90提取物显示出对糖酶,α-氨基酶,α-葡萄糖酶和马尔塔酶的优异抑制,以及显著的抗氧化活性 (ABTS,基,FRAP).
结论:
- A90溶剂是提取高抗氧化和抗糖尿病活性的Galega officinalis化合物的最佳方法.
- 官的提取物,特别是A90的提取物,显示出作为治疗糖尿病和氧化应激的天然药物的有前途潜力.
- 对特定生物活性化合物和体内疗效的进一步研究是有必要的.
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
160
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
160
01:23Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
01:06Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
175
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
175
01:24Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300